内容紹介
Summary
A 50s man receiving dialysis for chronic kidney disease due to IgA nephropathy underwent laparoscopic reversal via Hartmann's procedure for rectal cancer and multiple liver metastases, followed by chemotherapy for the liver metastases. Following a single course of mFOLFOX therapy, bevacizumab was administered for 8 courses, resulting in tumor shrinkage and a decrease in tumor marker levels. The initial doses were 60 mg/m2 oxaliplatin and 280(bolus injection)and 1,680 mg/m2(continuous infusion)of 5-FU. Subsequently, these doses were adjusted to be administered every 3 weeks. No serious adverse events other than neutropenia(Grade 3), anorexia(Grade 1), and hiccups(Grade 1)were noted.
要旨
症例はIgA腎症による慢性腎臓病にて透析導入をされている50歳台,男性。直腸癌・多発肝転移にて腹腔鏡下ハルトマン手術施行後,肝転移に対する化学療法を施行した。mFOLFOX療法2コース目よりbevacizumabを追加し,8コース終了後には腫瘍縮小,腫瘍マーカーの低下を認めた。好中球減少(Grade 3),食欲不振(Grade 1)と吃逆(Grade 1)を認めた以外は重篤な有害事象もなく2017年7月までに8コースを終了し,1回目の評価ではPR inで,2回目の評価も継続でPRである。
目次
A 50s man receiving dialysis for chronic kidney disease due to IgA nephropathy underwent laparoscopic reversal via Hartmann's procedure for rectal cancer and multiple liver metastases, followed by chemotherapy for the liver metastases. Following a single course of mFOLFOX therapy, bevacizumab was administered for 8 courses, resulting in tumor shrinkage and a decrease in tumor marker levels. The initial doses were 60 mg/m2 oxaliplatin and 280(bolus injection)and 1,680 mg/m2(continuous infusion)of 5-FU. Subsequently, these doses were adjusted to be administered every 3 weeks. No serious adverse events other than neutropenia(Grade 3), anorexia(Grade 1), and hiccups(Grade 1)were noted.
要旨
症例はIgA腎症による慢性腎臓病にて透析導入をされている50歳台,男性。直腸癌・多発肝転移にて腹腔鏡下ハルトマン手術施行後,肝転移に対する化学療法を施行した。mFOLFOX療法2コース目よりbevacizumabを追加し,8コース終了後には腫瘍縮小,腫瘍マーカーの低下を認めた。好中球減少(Grade 3),食欲不振(Grade 1)と吃逆(Grade 1)を認めた以外は重篤な有害事象もなく2017年7月までに8コースを終了し,1回目の評価ではPR inで,2回目の評価も継続でPRである。